The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acceleron Pharma Inc. | COM | 00434H108 | 11,876 | 244,756 | SH | SOLE | 244,756 | 0 | 0 | ||
| Adaptimmune Therapeutics PLC | SPONDS ADR | 00653A107 | 8,309 | 700,000 | SH | SOLE | 700,000 | 0 | 0 | ||
| Aerie Pharmaceuticals, Inc. | COM | 00771V108 | 98,944 | 1,464,749 | SH | SOLE | 1,464,749 | 0 | 0 | ||
| Aimmune Therapeutics, Inc. | COM | 00900T107 | 90,263 | 3,356,749 | SH | SOLE | 3,356,749 | 0 | 0 | ||
| Alder BioPharmaceuticals, Inc. | COM | 014339105 | 26,642 | 1,686,220 | SH | SOLE | 1,686,220 | 0 | 0 | ||
| BioDelivery Sciences International, Inc. | COM | 09060J106 | 90 | 30,500 | SH | SOLE | 30,500 | 0 | 0 | ||
| Denali Therapeutics Inc. | COM | 24823R105 | 3,813 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| Epizyme, Inc. | COM | 29428V104 | 19,894 | 1,468,215 | SH | SOLE | 1,468,215 | 0 | 0 | ||
| Insmed Incorporated | COM | 457669307 | 22,885 | 967,636 | SH | SOLE | 967,636 | 0 | 0 | ||
| Sangamo Therapeutics, Inc. | COM | 800677106 | 1,143 | 80,500 | SH | SOLE | 80,500 | 0 | 0 | ||